

Welcome

Dear Colleagues,

We are pleased to invite you to the 3rd International MRD Symposium, which will be held in Kiel, Germany, from 25 to 27 September 2025.

This symposium will provide a comprehensive overview of Measurable Residual Disease (MRD) detection methods and their standardization, with a particular focus on the clinical application in various hematological malignancies in both pediatric and adult patients. A central objective of the meeting will be to achieve a consensus on key MRD-related topics, which we aim to publish as a joint statement.

To this end, we will bring together leading international experts from clinical study groups, laboratory research and methodology development to facilitate an interdisciplinary exchange of knowledge and expertise. Through keynote lectures, panel discussions and interactive sessions the symposium will offer an opportunity to discuss current challenges, novel approaches and future perspectives in MRD research and its implementation in clinical practice.

We look forward to a stimulating and productive meeting and cordially invite you to participate.

Yours,


Monika Brüggemann
on behalf of the Kiel team


Christiane Pott



General Information

Registration and Payment

To confirm your participation, please follow the link to register:

<https://futura.umfragen.uni-kiel.de/683324?lang=en>

The participation fee is € 200 and can be paid by bank transfer / partially possible by scanning the QR code in your banking app, depending on your bank. Please ensure that payment is completed to guarantee your place at the symposium. Please register for the symposium as early as possible, as the number of participants is limited.



Bank Details for Payment

Account Name: Universitätsklinikum Schleswig-Holstein
IBAN: DE30 2307 0710 0872 0815 00
BIC: DEUTDEHH222

Reference: F 374550 MRD Symposium 2025 – [Your Name]

Hotel recommendation

Maritim Hotel Kiel – please book by sending an email at your earliest to info.bki@maritim.de mentioning the booking code „MRD Symposium 2025“ to receive the negotiated rate. The following hotels have also a negotiated rate and can be booked with the booking code „UKSH“:
Unique by ATLANTIC: www.unique-atlantic.de/en/hotel-kiel
B&B Hotel: www.hotel-bb.com/de/stadt/hotels-kiel
Steigenberger Conti Hansa: www.hrewards.com/de/steigenberger-conti-hansa-kiel

Sponsors

	10.000 €		5.000 €
	5.000 €		5.000 €
	5.000 €		5.000 €
	5.000 €		5.000 €
	5.000 €		10.000 €

Contact

Universitätsklinikum Schleswig-Holstein
Hematology Lab
Head of Hematology Laboratory Unit
Prof. Dr. Monika Brüggemann
Arnold-Heller-Str. 3, D-24105 Kiel
www.uksh.de/haematologielabor-kiel

Organisation

Mira Jungjohann
☎ +49 431 500–249 97, 📠 -24 974
✉ mira.jungjohann@uksh.de

Venue information

Maritim Hotel Bellevue
Bismarckallee 2, 24105 Kiel
☎ +49 431 389 40



Wissen schafft Gesundheit



UNIVERSITÄTSKLINIKUM
Schleswig-Holstein

Campus Kiel



Hämatologie
Labor Kiel



UCCSH

Universitäres Cancer Center
Schleswig-Holstein

3rd International Symposium
on MRD in Hematological Malignancies

September 25–27, 2025

Program September 25 – 27, 2025

September 25, 2025

Time	Topic
14.00	Opening
14.15	Keynote lecture 1: How MRD may change the modern treatment of AML <i>Francesco Buccisano</i>
	Session I: MRD in AML: technical aspects and clinical implication
14.45	How we define MRD in AML <i>Michael Heuser</i>
15.10	Advantages of DNA-based MRD detection in AML <i>Jan Trka</i>
15.35	AI applied to MRD detection <i>Sylvie Freeman</i>
16.00	MRD in less-intensive regimens <i>Jacqueline Cloos</i>
16.30	Break
	Session II: MRD – State of the art in myeloma
17.00	MRD monitoring in myeloma: state of the art <i>Ramón García Sanz</i>
17.20	Added value of mass spectrometry and imaging <i>Leo Rasche</i>
17.40	Significance of MRD outside clinical trials <i>Katja Weisel</i>
18.15	Industry sponsored satellite Cutting edge diagnostics in hematology
19.30	Dinner Maritim Hotel

The MRD Symposium is accredited by the Medical Association of Schleswig-Holstein and is designated for 18 credit points Category A.

September 26, 2025

Time	Topic
8.30	Keynote lecture 2: MRD in ALL – A success story of 30 years of European cooperation <i>Jacques JM van Dongen</i>
	Session III: MRD assessment in ALL – technical aspects
9.00	IG/TR-based MRD monitoring <i>Monika Brüggemann</i>
9.20	EuroMRD guidelines for BCR::ABL1 assessment in ALL <i>Heike Pfeifer</i>
9.40	How to monitor MRD in BCR::ABL1 positive ALL <i>Emmanuelle Clappier</i>
9.55	MRD assessment in KMT2A-rearranged ALL <i>Gianni Cazzaniga</i>
10.10	Flow-based and molecular MRD quantification: are the results interchangeable? <i>Vincent van der Velden</i>
10.30	Break
	Session IV: How to measure, report and interpret MRD in ALL
11.00	Current status of age-overriding MRD assessment in ALL – results from the Surveys and Delphi Polls <i>Michaela Kotrova</i>
11.30	Flash Talks of representatives of clinical trials on pediatric and adult ALL
12.15	Round table discussion: <i>Julia Alten, Nicolas Boissel, Monika Brüggemann, Gunnar Cario, Gianni Cazzaniga, Sabina Chiaretti, Emmanuelle Clappier, Kiss Csongor, Cornelia Eckert, Adele Fielding, Nicola Gökbüget, Michaela Kotrova, John Moppett, Josep Maria Ribera, Carmelo Rizzari, Martin Schrappe, Dave Teachey, Jan Trka, Vincent van der Velden, Jacques JM van Dongen, Bela Wrench</i>
13.00	Lunch

	Session V: Liquid biopsies for MRD assessment in mature lymphoid malignancies – techniques
14.00	Capture sequencing using cell-free DNA <i>Gianluca Gaidano</i>
14.20	IG amplicon sequencing using cell-free DNA <i>Leo Meriranta</i>
14.40	Preanalytics and technical requirements for MRD using cfDNA: which standards do we need? <i>Mouhamad Khouja</i>
15.00	Break
	Session VI: Liquid biopsies for MRD assessment in mature lymphoid malignancies – clinical impact
15.30	Management of aggressive lymphomas, combination of ctDNA and PET for response assessment <i>Davide Rossi</i>
15.45	ctDNA MRD: thresholds and required sensitivity in clinical application <i>Stefan Alig</i>
16.00	ctDNA based diagnostics in CSF: requirements, specificity and clinical application <i>Florian Scherer</i>
16.15	ctDNA based diagnostics in Hodgkin – clinical implications and time points for measurement of MRD <i>Sven Borchman</i>
16.30	Current status of clinical application and recommendations: report of the Delphi poll <i>Simone Ferrero</i>
16.45	Round table discussion: Preanalytics, general recommendations and guidelines for liquid biopsies for MRD assessment in mature lymphoid malignancies. <i>Stefan Alig, Gianluca Gaidano, David Gonzalez de Castro, Mouhamad Khouja, Simone Ferrero, Christiane Pott, Davide Rossi, Sven Borchmann, Paul Bröckelmann, Sirpa Leppä, Vincent Camus, Leo Meriranta, Marco Ladetto, Marie-Helen Delfau, Cédric Rossi, Peter Stewart</i>
18.30	Dinner Bootshaus Kiel (Düsternbrooker Weg 16)

September 27, 2025

Time	Topic
	Early morning workshops in parallel (only for participants of the round table discussions): Expert discussion to reach consensus on presented topics
8.00	A Development of consensus guidelines on how to measure, report and interpret MRD in ALL (Participants of Session III / Round Table Discussion I)
8.00	B Developments of consensus guidelines on technical requirements for liquid biopsies for MRD detection (Participants of Session IV and V / Round Table Discussion II)
9.00	Keynote lecture 3: Biomarkers in clinical trials in the past, present and future <i>Martin Schrappe</i>
	Session VI:MRD assessment in times of increasing regulation – Significance of the IVDR for patient care and clinical studies
9.30	IVDR – the regulatory basis <i>Bart Lubbers</i>
9.50	In-house in vitro diagnostics in the era of IVDR – the AWMF perspective <i>Albrecht Stenzinger</i>
10.10	The IVDR and the potential impact on clinical trials – the COMBINE project <i>Elizabeth Macintyre</i>
10.30	Break
	Session VII: MRD – State of the art in CLL
11.00	CLL MRD: threshold, methods, timepoints <i>Matthias Ritgen</i>
11.25	Is bone marrow still needed for MRD assessment in CLL? <i>Anton W Langerak</i>
11.50	Modelling MRD including disease stage, distribution and type and time-point of therapy <i>Othman Al-Sawaf</i>
	Summary and future perspectives
12.15	How to measure, report and interpret MRD in ALL <i>Monika Brüggemann</i>
12.30	Significance of liquid biopsies for MRD assessment in mature lymphoid malignancies <i>Christiane Pott</i>
13.00	Closing remarks and lunch packages